This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Consultation: AAC Consensus Pathway for Uncontrolled and Severe Asthma

The consultation is now open, please take part in providing your feedback using this survey before 23.59 Monday 31st January 2022. You will only be able to access this link once.


A key workstream of the AAC Asthma Biologics RUP focuses on the development of a “Consensus Pathway” for uncontrolled and severe asthma. The rationale for this being that severe asthma currently falls outside of NICE guidelines, and whilst there is guidance and service criteria for elements of the pathway (i.e primary care, tertiary care or biologics prescribing), there is no single guidance document that brings together all parts of the pathway and offer guidance on acceptable timeframes at each stage.

The consensus pathway would act not as a formal set of guidelines, but as a tool to inform and raise awareness of consensus best practice and to start conversations locally and regionally about redefining asthma pathways with uncontrolled and severe asthma in mind.

Chaired by Dr Hitasha Rupani, a sub-group was formed to create a specification for the pathway and to develop its content. The group included membership from a broad range of stakeholder organisations involved in asthma care. The group agreed an overall approach and vision for the consensus pathway. Key clinical leaders in different care settings then took ownership of the different elements of the pathway, including the assessment and management of uncontrolled asthma and severe asthma in primary and secondary care, future service structures and links with severe asthma centres.

The pathway development leveraged insight gathered from recent research and evaluations including the AAC NICE adoption scoping report; AHSN Network Severe Asthma Benchmarking exercise; AAC Asthma UK Patient Journey time audit and a recent Delphi consensus study of best practice for referral and management of Asthma.

Through a series of focused workshops on the different elements of the pathway and collaborative working the group have produced a draft consensus pathway. Comments and challenges were taken and worked through by the group to eventually reach a draft consensus pathway.

You can now review and comment on this draft consensus pathway and supporting documentation for primary care, secondary care and severe asthma centres.

The consultation process                            

We invite comments on a draft version of the pathway.

After closure of the consultation process the core team of clinical leads supported by Oxford AHSN will review the comments relevant to sections and propose any relevant changes suggested. A final review and approval meeting will be held at the end of February 2022 to agree changes within the AAC Consensus Pathway Group.

Consultation period:                                     4th January 2022 – 31st January 2022

Final review and approval:                          February 2022

Expected publication:                                   March 2022


Purpose of the consultation and documentation                    

The AAC consensus pathway group would like to offer those involved in asthma care an opportunity to feedback on the proposed pathways, challenges in attainment of any of the specified elements and share any evidence that does not support the criteria specified in the pathway.

We wanted to gather structured  feedback on all elements of the pathway overview, and the detail broken down for each care setting:

We appreciate the fact that people who will be providing their comments may not have opinion on all of the sections, however, we would welcome your opinion on one or more of the sections where you feel confident about.

How to comment: please use this link to go to Survey Monkey data collection tool

Any identifiable information gathered in the survey will be used solely for analysis and all responses will be kept anonymous.

Deadline: Monday 31st January 2022 at 23:59

Email enquiries                  If you have any queries please email